Clinical Trial

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

Study acronym: LaPemERLA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study testing the combination of Pembrolizumab with Lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR1-4), ret protooncogene (RET), platelet-derived growth factor receptor-alpha (PDGFR-alpha) and KIT (a stem cell factor receptor), and letrozole, a non-steroidal aromatase inhibitor, in advanced hormone receptor (HR) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) that has progressed on/after standard endocrine therapy.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-15
critical Primary endpoint(s) modified 2026-04-07
notable Primary completion pushed: 2025-12-31 -> 2026-12-31 2026-04-07
minor Completion pushed: 2027-12-31 -> 2028-12-31 2026-04-07
Trial Details
NCT Number NCT05286437
Lead Sponsor National Cancer Centre, Singapore
Collaborators: MSD Pharma (Singapore) Pte Ltd
Conditions Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Enrollment 40 participants
Start Date 2023-02-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14